Granulocytes and monocytes apheresis induces upregulation of TGFβ1 in patients with active ulcerative colitis: A possible involvement of soluble HLA-I

Journal of Clinical Apheresis

Volumn 32, Issue 1, 2017, Pages 49-55

  Contini, Paola ^a   Negrini, Simone ^a   Bodini, Giorgia ^a   Trucchi, Cecilia ^a   Ubezio, Gianluca ^a   Strada, Paolo ^a   Savarino, Vincenzo ^a   Ghio, Massimo ^a  

^a UNIVERSITY OF GENOA   (Italy)

Author keywords

granulocytes and monocytes apheresis; inflammatory bowel diseases; sFasL; sHLA I; TGF 1

Indexed keywords

AZATHIOPRINE; CELLULOSE ACETATE; FAS LIGAND; HLA ANTIGEN CLASS 1; TRANSFORMING GROWTH FACTOR BETA1; MICROSPHERE;

ADULT; AGED; APHERESIS; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; FEMALE; GRANULOCYTE AND MONOCYTE APHERESIS; HUMAN; HUMAN CELL; MALE; NEUTROPHIL; PROSPECTIVE STUDY; PROTEIN BLOOD LEVEL; THERAPY EFFECT; ULCERATIVE COLITIS; UPREGULATION; CENTRIFUGATION; COLITIS, ULCERATIVE; CYTOLOGY; GENETICS; GRANULOCYTE; IMMUNOADSORPTION; IMMUNOLOGY; IMMUNOSUPPRESSIVE TREATMENT; LEUKAPHERESIS; MONOCYTE; PHYSIOLOGY; PROCEDURES; SOLUBILITY;

BLOOD COMPONENT REMOVAL; CENTRIFUGATION; COLITIS, ULCERATIVE; GRANULOCYTES; HISTOCOMPATIBILITY ANTIGENS CLASS I; HUMANS; IMMUNOSORBENT TECHNIQUES; IMMUNOSUPPRESSION; LEUKAPHERESIS; MICROSPHERES; MONOCYTES; SOLUBILITY; TRANSFORMING GROWTH FACTOR BETA1; UP-REGULATION;

EID: 84963600774     PISSN: 07332459     EISSN: 10981101     Source Type: Journal    
DOI: 10.1002/jca.21466     Document Type: Article

References (42)

1. Schwartz J, Winters JL, Padmanabhan A, Balogun RA, Delaney M, Linenberger ML, Szczepiorkowski ZM, Williams ME, Wu Y, Shaz BH. Guidelines on the use of therapeutic apheresis in clinical practice-evidence-based approach from the Writing Committee of the American Society for Apheresis: the sixth special issue. J Clin Apher 2013;28:145–284.
2. McLeod BC. Therapeutic apheresis: history, clinical application, and lingering uncertainties. Transfusion 2010;50:1413–1426.
3. Agishi T. Birth of the concept and the development of extracorporeal immunomodulation. Ther Apher 2002;6:312–316.
4. Abraham C, Cho JH. Inflammatory bowel disease. N Engl J Med 2009;361:2066–2078.
5. Danese S, Fiocchi C. Ulcerative colitis. N Engl J Med 2011;365:1713–1725.
6. Dassopoulos T, Cohen RD, Scherl EJ, Schwartz RM, Kosinski L, Regueiro MD. Ulcerative colitis care pathway. Gastroenterology 2015;149:238–245.
7. Saniabadi AR, Hanai H, Takeuchi K, Umemura K, Nakashima M, Adachi T, Shima C, Bjarnason I, Lofberg R. Adacolumn, an adsorptive carrier based granulocyte and monocyte apheresis device for the treatment of inflammatory and refractory diseases associated with leukocytes. Ther Apher Dial 2003;7:48–59.
8. Hasegawa M, Watanabe A, Takahashi H, Takahashi K, Kasugai M, Kawamura N, Kushimoto H, Murakami K, Tomita M, Nabeshima K, Oohashi A, Kondou F, Ooshima H, Hiki Y, Sugiyama S. Treatment with cytapheresis for antineutrophil cytoplasmic antibody-associated renal vasculitis and its effect on anti-inflammatory factors. Ther Apher Dial 2005;9:297–302.
9. Sawada K, Masaki N, Hayashi S, Zeniya M, Ishikawa T, Takahashi H, Ohnishi K, Fukunaga K, Hara N, Yamamoto T, Hada T, Toda G. Immunomodulatory effects of selective leucocytapheresis as a new adjunct to interferon-alpha2b plus ribavirin combination therapy: a prospective study in patients with high plasma HCV viraemia. J Viral Hepat 2005;12:274–282.
10. Namba K, Sonoda KH, Kitamei H, Shiratori K, Ariyama A, Iwabuchi K, Onoe K, Saniabadi AR, Inaba S, Ishibashi T, Ohno S. Granulocytapheresis in patients with refractory ocular Behcet's disease. J Clin Apher 2006;21:121–128.
11. Mori S, Nagashima M, Yoshida K, Yoshino K, Aoki M, Kawana S, Hirata I, Saniabadi A, Yoshino S. Granulocyte adsorptive apheresis for leg ulcers complicated by rheumatoid arthritis: a report on three successfully treated cases. Int J Dermatol 2004;43:732–735.
12. Bazzichi L, Giuliano T, Rossi A, Mazzoni A, Grazzini T, De Feo F, Giacomelli C, Scatena F, Bombardieri S. Partial remission of refractory RA after Adacolumn cytapheresis: a case report. Rheumatol Int 2008;28:295–297.
13. Saniabadi AR, Tanaka T, Ohmori T, Sawada K, Yamamoto T, Hanai H. Treating inflammatory bowel disease by adsorptive leucocytapheresis: a desire to treat without drugs. World J Gastroenterol 2014;20:9699–9715.
14. Hanai H, Takeda Y, Eberhardson M, Gruber R, Saniabadi AR, Winqvist O, Lofberg R. The mode of actions of the Adacolumn therapeutic leucocytapheresis in patients with inflammatory bowel disease: a concise review. Clin Exp Immunol 2011;163:50–58.
15. Waitz G, Petermann S, Liebe S, Emmrich J, Ramlow W. Reduction of dendritic cells by granulocyte and monocyte adsorption apheresis in patients with ulcerative colitis. Dig Dis Sci 2008;53:2507–2515.
16. Ghio M, Contini P, Mazzei C, Brenci S, Barberis G, Filaci G, Indiveri F, Puppo F. Soluble HLA class I, HLA class II, and Fas ligand in blood components: a possible key to explain the immunomodulatory effects of allogeneic blood transfusions. Blood 1999;93:1770–1777.
17. Ghio M, Contini P, Negrini S, Proietti M, Gonella R, Ubezio G, Ottonello L, Indiveri F. sHLA-I contaminating molecules as novel mechanism of ex vivo/in vitro transcriptional and posttranscriptional modulation of transforming growth factor-beta in CD8+ T lymphocytes and neutrophils after intravenous immunoglobulin treatment. Transfusion 2010;50:547–555.
18. Ghio M, Contini P, Ottonello L, Arduino N, Gringeri A, Indiveri F, Dallegri F, Puppo F. Effect of clotting factors concentrates on lymphocyte and neutrophil function in vitro. Thromb Haemost 2003;89:365–373.
19. Ghio M, Contini P, Ubezio G, Ansaldi F, Setti M, Tripodi G. Transient transforming growth factor beta1 modulation in monocytes and natural killer cells following plasma or plasma–platelet apheresis donation procedures. Blood Transfus 2015;13:684–686.
20. Ghio M, Bertolotto M, Ottonello L, Contini P, Ubezio G, Tripodi G. Transient inhibition of neutrophil migration following plasma or plasma-platelet apheresis donation procedures. Blood Transfus 2015;13:682–683.
21. Ghio M, Contini P, Ansaldi F, Ubezio G, Setti M, Risso M, Tripodi G. Immunomodulation due to plasma or plasma-platelet apheresis donation: events occurring during donation procedures. J Clin Apher 2015;30:204–211.
22. Ghio M, Contini P, Ansaldi F, Ubezio G, Setti M, Risso M, Tripodi G. Donor neutrophil activation and transforming growth factor-beta1 modulation induced by donor apheresis procedures. Blood Transfus 2014;12:615–617.
23. Ghio M, Contini P, Ansaldi F, Ubezio G, Setti M, Risso M, Tripodi G. A possible role of soluble HLA-I molecule in the immunomodulatory effects of therapeutic apheresis. Blood Transfus 2014;12Suppl1:s167–s169.
24. Ottonello L, Ghio M, Contini P, Bertolotto M, Bianchi G, Montecucco F, Colonna M, Mazzei C, Dallegri F, Indiveri F. Nonleukoreduced red blood cell transfusion induces a sustained inhibition of neutrophil chemotaxis by stimulating in vivo production of transforming growth factor-beta1 by neutrophils: role of the immunoglobulinlike transcript 1, sFasL, and sHLA-I. Transfusion 2007;47:1395–1404.
25. Puppo F, Contini P, Ghio M, Brenci S, Scudeletti M, Filaci G, Ferrone S, Indiveri F. Soluble human MHC class I molecules induce soluble Fas ligand secretion and trigger apoptosis in activated CD8(+) Fas (CD95)(+) T lymphocytes. Int Immunol 2000;12:195–203.
26. Silverberg MS, Satsangi J, Ahmad T, Arnott ID, Bernstein CN, Brant SR, Caprilli R, Colombel JF, Gasche C, Geboes K, Jewell DP, Karban A, Loftus EV, Jr., Pena AS, Riddell RH, Sachar DB, Schreiber S, Steinhart AH, Targan SR, Vermeire S, Warren BF. Toward an integrated clinical, molecular and serological classification of inflammatory bowel disease: report of a Working Party of the 2005 Montreal World Congress of Gastroenterology. Can J Gastroenterol 2005;19SupplA:5A–36A.
27. Rutgeerts P, Sandborn WJ, Feagan BG, Reinisch W, Olson A, Johanns J, Travers S, Rachmilewitz D, Hanauer SB, Lichtenstein GR, de Villiers WJ, Present D, Sands BE, Colombel JF. Infliximab for induction and maintenance therapy for ulcerative colitis. N Engl J Med 2005;353:2462–2476.
28. Ghio M, Contini P, Setti M, Ubezio G, Mazzei C, Tripodi G. sHLA-I Contamination, a novel mechanism to explain ex vivo/in vitro modulation of IL-10 synthesis and release in CD8(+) T lymphocytes and in neutrophils following intravenous immunoglobulin infusion. J Clin Immunol 2010;30:384–392.
29. Cuadrado E, Alonso M, de Juan MD, Echaniz P, Arenas JI. Regulatory T cells in patients with inflammatory bowel diseases treated with adacolumn granulocytapheresis. World J Gastroenterol 2008;14:1521–7.
30. Nagase K, Fukunaga K, Kashiwamura S, Kono T, Kamikozuru K, Yokoyama Y, Hida N, Ohda Y, Takeda N, Yoshida K, Iimuro M, Kikuyama R, Kato K, Miwa H, Matsumoto T. Immunoregulatory effects of adsorptive granulocyte and monocyte apheresis in patients with drug refractory Crohn's disease. Ther Apher Dial 2011;15:367–373.
31. Jimma F, Takeda Y, Kaneda K, Wakabayashi I. Induction of Foxp3 expression in T cells by cellulose acetate beads in vitro. J Clin Apher 2010;25:216–222.
32. Nishise S, Abe Y, Nomura E, Sato T, Sasaki Y, Iwano D, Yagi M, Sakuta K, Shibuya R, Mizumoto N, Kanno N, Ueno Y. Effect of cellulose acetate beads on the release of transforming growth factor-beta. Ther Apher Dial 2015;19:330–335.
33. Yoshimura A, Muto G. TGF-beta function in immune suppression. Curr Top Microbiol Immunol 2011;350:127–147.
34. Kajdaniuk D, Marek B, Borgiel-Marek H, Kos-Kudla B. Transforming growth factor beta1 (TGFbeta1) in physiology and pathology. Endokrynol Pol 2013;64:384–396.
35. Oh SA, Li MO. TGF-beta: guardian of T cell function. J Immunol 2013;191:3973–3979.
36. Pakyari M, Farrokhi A, Maharlooei MK, Ghahary A. Critical role of transforming growth factor beta in different phases of wound healing. Adv Wound Care 2013;2:215–224.
37. Finnson KW, McLean S, Di Guglielmo GM, Philip A. Dynamics of transforming growth factor beta signaling in wound healing and scarring. Adv Wound Care 2013;2:195–214.
38. Takeda Y, Shiobara N, Saniabadi AR, Adachi M, Hiraishi K. Adhesion dependent release of hepatocyte growth factor and interleukin-1 receptor antagonist from human blood granulocytes and monocytes: evidence for the involvement of plasma IgG, complement C3 and beta2 integrin. Inflamm Res 2004;53:277–283.
39. Saniabadi AR, Hanai H, Fukunaga K, Sawada K, Shima C, Bjarnason I, Lofberg R. Therapeutic leukocytapheresis for inflammatory bowel disease. Transfus Apher Sci 2007;37:191–200.
40. Meyer A, Wang W, Qu J, Croft L, Degen JL, Coller BS, Ahamed J. Platelet TGF-beta1 contributions to plasma TGF-beta1, cardiac fibrosis, and systolic dysfunction in a mouse model of pressure overload. Blood 2012;119:1064–1074.
41. Sands BE, Sandborn WJ, Feagan B, Lofberg R, Hibi T, Wang T, Gustofson LM, Wong CJ, Vandervoort MK, Hanauer S, Adacolumn Study G. A randomized, double-blind, sham-controlled study of granulocyte/monocyte apheresis for active ulcerative colitis. Gastroenterology 2008;135:400–409.
42. Sands BE, Katz S, Wolf DC, Feagan BG, Wang T, Gustofson LM, Wong C, Vandervoort MK, Hanauer S. A randomised, double-blind, sham-controlled study of granulocyte/monocyte apheresis for moderate to severe Crohn's disease. Gut 2013;62:1288–1294.